Table 1.
Characteristics of generated VST lines
| VST line compound no. | CMV specificity, SFC/1 × 105 IE1 | CMV specificity, SFC/1 × 105 pp65 | CD3, % | CD4, % | CD8, % | CD56, % | CD45RO+/CD62L+, % | CD45RO+/CD62L–, % | HLA-A | HLA-B | HLA-DR | HLA-DQ | No. of patients screened* | No. of patients treated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6790 | 127 | 1186 | 97.81 | 74.23 | 19.48 | 3.88 | 75.45 | 16.33 | 02,33 | 15,44 | 07,13 | 02,06 | 4 | 3 |
| 6798 | 612 | 805 | 98.79 | 17.75 | 75.73 | 4.05 | 40.3 | 44.83 | 02,02 | 40,52 | 04,08 | 03,03 | 6 | 4 |
| 6802 | 113 | 1354 | 99.66 | 5.20 | 92.82 | 1.69 | 69.75 | 27.51 | 11,23 | 35,57 | 01,07 | 03,05 | 1 | 0 |
| 6808 | 827 | 986 | 99.77 | 12.59 | 83.18 | 3.10 | 74.09 | 20.13 | 02,24 | 40,52 | 04,13 | 03,06 | 4 | 1 |
| 6814 | 639 | 2573 | 99.68 | 28.25 | 69.85 | 0.99 | 41.56 | 55.78 | 02, 24 | 08,14 | 01, 03 | 02,05 | 1 | 1 |
| 6823 | 700 | 717 | 99.39 | 10.99 | 86.49 | 1.51 | 47.59 | 48.59 | 11,68 | 07,35 | 03,07 | 02,02 | 3 | 1 |
| 6834 | 128 | 725 | 99.77 | 15.40 | 82.90 | 2.27 | 64.64 | 32.72 | 02,24 | 15,35 | 04,09 | 03,03 | 6 | 1 |
| 6838 | 205.5 | 211 | 99.75 | 5.57 | 87.46 | 8.76 | 54.50 | 36.42 | 02,30 | 13,35 | 07,08 | 02,06 | 1 | 0 |
*
Indicates how frequently the VST lines were determined to be the most suitable line for a screened patient.